Fosamax Exposure Linked to Osteonecrosis of the Jaw: Mechanisms and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

General Health Context and Medication Safety

The legacy theme of general health and science information provides broad, foundational knowledge about the human body and common medical conditions. This context often includes discussions of medication safety, bone health, and the importance of informed patient care. Within this framework, the transition to a more specialized concern begins by narrowing the focus to a specific pharmaceutical agent and its potential adverse effects. The target query introduces a particular drug, Fosamax, and a serious condition, osteonecrosis of the jaw, shifting the discussion from general health principles to a focused risk assessment. This pivot moves the narrative from a broad educational scope toward an occupational exposure concern, where the primary interest lies in understanding the link between a specific medication and a localized pathological outcome.

Bridge: From General Health to Specific Risk

The bridge concept facilitates this shift by connecting the general health context—which encompasses medication use and bone physiology—to the more targeted inquiry of Fosamax exposure and the associated risk of osteonecrosis of the jaw. This transition maintains a neutral academic tone, avoiding mechanistic claims or citations, and instead establishes a clear pathway from general health literacy to a specific, occupationally relevant question about causation and risk.

Fosamax and Osteonecrosis of the Jaw: Clinical Presentation and Risk Factors

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. This narrative reviews the clinical presentation, pharmacological mechanisms, and causation considerations linking Fosamax exposure to ONJ, based on available evidence. Osteonecrosis of the jaw can occur spontaneously, but it is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to ONJ

Mechanistic pathways linking Fosamax to ONJ involve the drug's effects on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. The jawbone may be particularly susceptible due to its high remodeling rate and exposure to mechanical stress from chewing. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies in estrogen-deficient rats treated with alendronate have examined effects on the jawbone, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate treatment alters the mechanical and structural properties of jawbone, potentially contributing to ONJ development.

Causation Considerations and Evidence Summary

Causation considerations for affected patients require careful evaluation of the temporal relationship between Fosamax exposure and ONJ onset. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information, which includes a dedicated section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label notes that in placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may complicate risk communication. In summary, Fosamax exposure is linked to ONJ through mechanisms involving suppressed bone turnover and altered jawbone properties. The evidence supports a causal association, particularly in patients with additional risk factors such as invasive dental procedures or prolonged bisphosphonate use. Clinicians should weigh the benefits of Fosamax for osteoporosis treatment against the risk of ONJ, especially in patients requiring dental interventions.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Fosamax and how is it used?

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region. Fosamax exposure has been associated with ONJ, particularly in patients with additional risk factors such as invasive dental procedures or prolonged bisphosphonate use. The risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the mechanisms by which Fosamax may cause ONJ?

Fosamax inhibits osteoclast-mediated bone resorption, suppressing normal bone turnover. The jawbone, with its high remodeling rate, may be particularly susceptible. Studies have shown that bisphosphonate treatment alters the mechanical and structural properties of jawbone, potentially contributing to ONJ development (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.